This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $1,041,646 to Cenna Biosciences Inc. to support the early clinical development of their modified P8 peptide drug candidate for the treatment of Alzheimer's disease. The key activities funded include Chemistry, Manufacturing, and Controls (CMC) work to enable clinical development, a pre-IND meeting with the FDA, IND submission, and the initiation of a Phase 1 clinical trial for the novel peptide drug. This award represents an important step in advancing a promising new therapeutic approach that aims to inhibit amyloid-beta production without directly targeting the secretase enzymes, which have been linked to safety issues in prior Alzheimer's drug trials.
Generated 4/1/25, 1:56 AM